What were the biggest dental headlines of 2025? From changes to the dental contract to industry innovations, explore this ...

Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

Billionaire investor Bill Ackman on Saturday proposed merging SpaceX with Pershing Square SPARC Holdings, a special purpose acquisition rights vehicle created by his firm, Pershing Square Capital ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. Structure, which concentrates on metabolic diseases with a ...

With prices holding above $2,750, the ETH/USD pair has the potential to rise 75% from the current levels toward $5,120, ...

Dec 8 (Reuters) - Structure Therapeutics said on Monday its obesity pill showed weight loss of up to 11.3% after 36 weeks of treatment in a mid-stage study, driving the company's shares more than 140% ...

Efficiency must be considered alongside the value councils bring – including driving growth, writes the chair of the District Councils’ Network. Power and Partnership: Foundations for Growth was the ...

Pinecone recently announced the public preview of Dedicated Read Nodes (DRN), a new capacity mode for its vector database ...

With the evolving dynamics for those studying abroad, particularly in light of global economic factors and changing visa policies, a report has revealed that affordability and post-study work ...